Intellia Therapeutics, Inc. (NTLA) announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational in vivo genome-editing candidate, Nexiguran ziclumeran (nex-z, also known as NTLA-2001). The regulatory body granted the RMAT designation to nex-z for the treatment of hereditary transthyretin (ATTR) amyloidosis with polyneuropathy (ATTRv-PN). The RMAT designation provides the candidate with increased opportunities to meet FDA officials, as well as arrang ...